Product name as reported
Mens Rogaine: adverse event reports filed with FDA
1,407 reports list it as a suspect or interacting product, 2015–2026.
- 1,407
- reports as suspect product
- 0% of all reports · about 128 a year
- 42
- reports, 12 months to June 2026
- 48 in the 12 months before
- 1.5%
- marked serious by the reporter
- 57.4% across all reports
- 0%
- record death among outcomes, as reported
- 0 reports · not verified by FDA
1,407 adverse event reports received by FDA list the product name "Mens Rogaine" as reporters wrote it as a suspect or interacting product, from July 2015 to June 2026. A further 16 reports list it only as a concomitant medication, and those are not counted in the figures on this page.
In the 12 months to June 2026, 42 reports listed it, down 12% from 48 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 128 reports a year and 0% of the 20,646,523 reports in the database. How many people take it is not in the data, so a count is not a rate of occurrence.
Reporters most often recorded product use issue (40.3%), intentional product misuse (23.6%) and off label use (19.8%). A report can list several reactions, so shares add to more than 100%; 96 different terms appear across these reports. Product use issue is recorded in 40.3% of these reports, against 0.9% of all reports in the database.
1.5% of the reports are marked serious by the reporter; 0% record death among the outcomes and 0.3% record hospitalisation, as reported. 98.9% of the reports came from consumers, and the largest patient age group is 18 to 44 (5%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Mens Rogaine reports recording the termall reports in the database
- Product use issuea problem in how the product was used40.3%567
- Intentional product misusedeliberate use not as intended23.6%332
- Off label useused for a purpose or in a way not on the label19.8%279
- Wrong patient received medication14.5%204
- Alopeciahair loss13.1%185
- Drug ineffectivethe medicine did not work as expected9.2%130
- Product use in unapproved indicationused for a purpose not on the label6.5%91
- Pruritusitching5.5%77
- Hair growth abnormal3.5%49
- Hair texture abnormal3.1%43
- Inappropriate schedule of drug administrationthe medicine was taken at the wrong times2.4%34
- Wrong technique in product usage processthe product was used in the wrong way2.1%29
- Application site pruritusitching where the product was applied2%28
- Drug prescribing errora prescribing mistake2%28
- Skin irritationirritated skin1.9%27
- Hair colour changes1.7%24
- Inappropriate schedule of product administrationthe product was taken at the wrong times1.6%22
- Skin exfoliationpeeling skin1.5%21
- Dandruff1.4%19
- Headachehead pain1.4%19
- Incorrect dose administeredthe wrong dose was given1.2%17
- Erythemaskin redness1.1%15
- Dry skindry skin1%14
- Rashskin rash0.9%12
- Overdosea dose above the recommended amount0.8%11
- Application site pain0.7%10
Top 30 of 96 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the share of all reports in the database; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 20,646,523 reports. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 99.3% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Alopecia | 327 | 23.2% |
| Hair growth abnormal | 11 | 0.8% |
| Accidental exposure to product | 5 | 0.4% |
| Diffuse alopecia | 2 | 0.1% |
| Madarosis | 2 | 0.1% |
The indication field is filled in by the reporter and is often blank; shares are of all 1,407 reports.
Drugs most often listed in the same reports
| Drug (any role in the report) | Reports | Share of Mens Rogaine reports |
|---|---|---|
| Mens Rogaine Extra Strength | 16 | 1.1% |
| Womens Rogaine | 11 | 0.8% |
| Vitamin d | 10 | 0.7% |
| Finasteride | 8 | 0.6% |
| Levothyroxine | 7 | 0.5% |
Other products listed in reports where Mens Rogaine is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.
In context
| Measure | Mens Rogaine | All reports |
|---|---|---|
| Reports as suspect product | 1,407 | 20,646,523 |
| Share of that pool | — | 0% |
| Reports, latest 12 months | 42 | 1,332,454 |
| Marked serious | 1.5% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 0 | 91 |
| Hospitalisation recorded, per 1,000 reports | 3 | 213 |
| Consumer-filed share | 98.9% | 45.8% |
| Top term, share of reports | Product use issue 40.3% | 0.9% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Questions about Mens Rogaine reports
How many adverse event reports has FDA received for Mens Rogaine?
1,407 reports list Mens Rogaine as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 42 of them arrived in the latest 12 months. Another 16 list it only as a concomitant medication.
What reactions are recorded in Mens Rogaine reports?
product use issue (40.3%), intentional product misuse (23.6%), off label use (19.8%), wrong patient received medication (14.5%) and alopecia (13.1%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Mens Rogaine was responsible.
How serious are the reports?
1.5% are marked serious by the reporter. Among the outcomes recorded, 0% of reports include death and 0.3% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
consumer or non-health professional (98.9%), other health professional (0.7%) and physician (0.2%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Mens Rogaine rising?
42 reports in the 12 months to June 2026, down 12% from 48 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Mens Rogaine was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Mens Rogaine?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Mens Rogaine as a suspect or interacting product; reports listing it only as a concomitant medication (16) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.